Medtronic has just received FDA approval for its Hugo surgical robot system in the U.S., positioning it as a potential growth opportunity similar to Intuitive Surgical's da Vinci system. With a P/E of 27 compared to Intuitive Surgical's 64, Medtronic appears undervalued and could see significant upside if Hugo achieves similar adoption rates. The company also offers a 2.9% dividend yield with decades of increases, making it attractive for dividend investors.

Medtronic is positioned as an attractive lifetime hold in the medical device sector, expanding into robotic surgery with FDA approval for its Hugo system. The company offers a compelling valuation (P/E of 16.3), a 48-year dividend increase streak with a 2.9% yield, and is spinning off its diabetes division to focus on faster-growing businesses. Recent Q3 results showed 8.7% revenue growth year-over-year.

Despite facing headwinds from tariffs and increased competition, Intuitive Surgical maintains a strong long-term outlook due to its competitive moat. The company's da Vinci robotic surgery system benefits from high switching costs, extensive clinical data, and continuous innovation. With an underpenetrated market, expanding indications, and growing demand from an aging population, the stock is positioned for superior returns over the next decade.

While Wall Street focuses on GLP-1 weight loss drugs from Novo Nordisk and Eli Lilly, surgical robotics pioneer Intuitive Surgical continues to thrive independently. The company's da Vinci robot installed base grew 12% to 11,106 units in 2025, with surgeries performed rising 18% year-over-year. Despite a high P/E ratio of 61, the stock trades below its five-year average of 71, offering potential for growth investors with AI integration and future autonomous surgery possibilities.

Intuitive Surgical is highlighted as a resilient medtech stock that could weather market downturns due to its dominant position in robotic surgery, strong competitive moat, recurring revenue from disposable instruments and service contracts, and essential nature of surgical procedures regardless of economic conditions. The company has demonstrated strong growth with stock gains of 100% over three years.

Intuitive Surgical, the world leader in robotic surgery, offers a compelling long-term investment opportunity due to its recurring revenue model. Beyond selling Da Vinci surgical systems, the company generates substantial revenue from disposable instruments and accessories that hospitals must continuously repurchase. In the recent quarter, instruments and accessories revenue ($1.6B) exceeded robotic systems revenue ($785M), creating a steady growth engine that justifies a buy-and-hold investment strategy.

Baxter International has cut its dividend significantly and faced a 75% stock decline over five years due to inconsistent revenue and negative earnings. However, the company's essential medical products, attractive valuation metrics, and strong demographic tailwinds from an aging population may appeal to turnaround and value investors, though recovery could be uneven and prolonged.

The global surgical staplers market is projected to grow from USD 6.41 billion in 2025 to USD 10.87 billion by 2033, at a CAGR of 6.87%. Growth is driven by increasing surgical volumes, adoption of minimally invasive procedures, and technological advancements in powered and disposable stapling systems. However, high device costs and stringent regulatory requirements pose challenges to market expansion.

Intuitive Surgical ended 2025 strongly with increased da Vinci robot placements and 18% growth in procedures performed. The company's business model is heavily weighted toward recurring revenue (75%) from instruments, accessories, and services. While AI integration presents future growth opportunities, the stock trades at a P/E ratio of 67x, significantly higher than the S&P 500's 28x. The author suggests long-term investors should be patient and wait for a potential deep sell-off before buying.

Intuitive Surgical, maker of the da Vinci surgical robot, is positioned at the forefront of AI-enhanced healthcare. With over 11,100 systems installed globally and an 18% year-over-year increase in surgeries performed, the company's vast database of surgical procedures represents a valuable asset for developing autonomous AI surgery. The FDA recently approved an AI enhancement to its Ion endoluminal system. While the stock trades at a premium 66 P/E ratio, aggressive growth investors may find the long-term AI opportunity compelling.

Abbott Laboratories and Intuitive Surgical are positioned for potential share price gains based on upcoming earnings reports. Abbott, a $211 billion healthcare giant, showed strong CGM product sales growth despite mixed Q3 results, while Intuitive Surgical reported impressive 18% YOY procedure growth and 19% revenue growth, though guidance for 2026 was more modest at 13-15% growth.

Intuitive Surgical reported strong Q4 2025 results with 19% revenue growth to $2.9 billion and procedure growth of 17% for Da Vinci systems and 44% for Ion systems. The company's recurring revenue (instruments, accessories, and services) represents 75% of total revenue, providing stability. However, the stock trades at a high 70x earnings valuation, and management guided for slower 13-15% procedure growth in 2026 versus 18% in 2025. The article suggests the stock could be a buy for long-term investors despite valuation risks.